Back to Search
Start Over
Poster: CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
- Source :
- Clinical Lymphoma Myeloma and Leukemia. 22:S140
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
- Subjects :
- Cancer Research
Oncology
Hematology
Subjects
Details
- ISSN :
- 21522650
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Clinical Lymphoma Myeloma and Leukemia
- Accession number :
- edsair.doi...........e10e180cc84f80da05c136c36ff22be6